Neuromuscular Blocking Agents

Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.

Also Known As:

Networked: 408 relevant articles (5 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Papazian, Laurent: 8 articles (12/2014 - 01/2004)
2.	Johansson, S G O: 8 articles (07/2012 - 01/2006)
3.	Florvaag, E: 7 articles (07/2012 - 01/2006)
4.	Mertes, P M: 5 articles (07/2014 - 01/2008)
5.	Eriksson, Lars I: 5 articles (06/2013 - 12/2010)
6.	Levy, Mitchell M: 5 articles (02/2013 - 03/2004)
7.	Gerlach, Herwig: 5 articles (02/2013 - 03/2004)
8.	Jaeschke, Roman: 5 articles (02/2013 - 01/2008)
9.	Vincent, Jean-Louis: 5 articles (02/2013 - 03/2004)
10.	Roch, Antoine: 5 articles (01/2013 - 01/2004)

Related Diseases

1.	Critical Illness (Critically Ill) 10/01/2015 - "Background Prolonged use of neuromuscular blocking agents (NMBAs) is very common in critically ill children both in pediatric and neonatal intensive care units. " 09/01/2014 - "Neuromuscular blocking agents (NMBAs) are used in a range of critical illnesses in neonates and infants, despite a lack of guidelines and professional standards. " 09/01/2013 - "Use of sedation and neuromuscular blockers in critically ill adults receiving high-frequency oscillatory ventilation." 06/01/2013 - "Finally a strategy for rational use of these sedative and neuromuscular blocking agents in critically ill patients will be proposed." 06/01/2011 - "Continuous-infusion neuromuscular blocking agents in critically ill neonates and children."
2.	Paralysis (Palsy) 05/01/2015 - "Quantitative neuromuscular monitoring is essential for studies of potency and duration of neuromuscular blocking agents, and for detecting residual paralysis in anesthetized patients. " 02/01/1996 - "Large, prospective, controlled studies are necessary to evaluate the incidence of prolonged paralysis or motor neuropathy with administration of neuromuscular blocking agents in patients whose dose is adjusted on the basis of peripheral nerve stimulation." 09/01/2014 - "Prolonged paralysis from non-depolarizing neuromuscular blocking agents: an evaluation of risk factors." 05/01/2009 - "Neuromuscular blocking agents are used to facilitate intubation and to establish muscle paralysis during surgery. " 05/01/2006 - "An estimated 24% to 70% of individuals have prolonged paralysis or severe weakness after receiving neuromuscular blocking agents (NMBAs) when therapy is terminated. "
3.	Craniocerebral Trauma (Head Injury) 09/01/1994 - "To investigate the efficacy of early, routine use of neuromuscular blocking agents for intracranial pressure management in patients with severe head injury. " 06/01/2007 - "Only 14% respondents still frequently use neuromuscular blocking agents, mostly in head injury patients. " 05/01/1998 - "Effect of neuromuscular blockers and opiates on the cerebrovascular response to endotracheal suctioning in adults with severe head injuries." 09/01/1994 - "Our findings suggest that early, routine, long-term use of neuromuscular blocking agents in patients with severe head injuries to manage intracranial pressure does not improve overall outcome and may actually be detrimental because of the prolongation of their ICU stay and the increased frequency of extracranial complications associated with pharmacologic paralysis. "
4.	Bipolar Disorder (Mania) 06/01/2007 - "Lithium is widely used for the treatment of bipolar disorders and can interact with neuromuscular blockers. "
5.	Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/01/2013 - "Randomized trials investigating neuromuscular blocking agents in adult acute respiratory distress syndrome (ARDS) have been inconclusive about effects on mortality, which is very high in this population. " 01/01/2013 - "Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials." 01/01/2012 - "Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials." 09/01/2015 - "The recent increase in use of neuromuscular blocking agents (NMBAs) in patients with acute respiratory distress syndrome is set against a backdrop of concerns about harm associated with use of these high-risk drugs. " 12/01/2014 - "Interest in the role of neuromuscular blocking agents (NMBAs) in the treatment of acute respiratory distress syndrome (ARDS) has been renewed since a recent randomized clinical trial showed a reduction in mortality associated with the use of NMBAs. "

Related Drugs and Biologics

1.	Atracurium (Tracrium)
2.	Adrenal Cortex Hormones (Corticosteroids)
3.	Lithium
4.	cisatracurium (Nimbex)
5.	Blood Glucose (Blood Sugar)
6.	Vasopressins (Vasopressin)
7.	Norepinephrine (Noradrenaline)
8.	Dopamine (Intropin)
9.	Dobutamine
10.	crystalloid solutions

Related Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation)
2.	Liver Transplantation
3.	Positive-Pressure Respiration (PEEP)
4.	Resuscitation
5.	Renal Dialysis (Hemodialysis)